UroGen Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell UroGen Pharma and other ETFs, options, and stocks.

About URGN

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. 

CEO
Elizabeth Barrett
CEOElizabeth Barrett
Employees
291
Employees291
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
2004
Founded2004
Employees
291
Employees291

URGN Key Statistics

Market cap
1.38B
Market cap1.38B
Price-Earnings ratio
-10.26
Price-Earnings ratio-10.26
Dividend yield
Dividend yield
Average volume
1.22M
Average volume1.22M
High today
$28.83
High today$28.83
Low today
$27.34
Low today$27.34
Open price
$28.05
Open price$28.05
Volume
542.18K
Volume542.18K
52 Week high
$32.37
52 Week high$32.37
52 Week low
$3.42
52 Week low$3.42

Stock Snapshot

With a market cap of 1.38B, UroGen Pharma(URGN) trades at $28.26. The stock has a price-to-earnings ratio of -10.26.

As of 2026-05-20, UroGen Pharma(URGN) stock has fluctuated between $27.34 and $28.83. The current price stands at $28.26, placing the stock +3.4% above today's low and -2.0% off the high.

UroGen Pharma(URGN) shares are trading with a volume of 542.18K, against a daily average of 1.22M.

In the last year, UroGen Pharma(URGN) shares hit a 52-week high of $32.37 and a 52-week low of $3.42.

In the last year, UroGen Pharma(URGN) shares hit a 52-week high of $32.37 and a 52-week low of $3.42.

URGN News

Investing.com 2d
H.C. Wainwright reiterates UroGen Pharma stock rating on durability data - Investing.com

...

H.C. Wainwright reiterates UroGen Pharma stock rating on durability data - Investing.com
TipRanks 5d
UroGen Pharma reports month results from UTOPIA trial

UroGen Pharma (URGN) announced UGN-103 achieved a 94.5% durability of response at six months by Kaplan-Meier estimate, in the ongoing Phase 3 UTOPIA trial of UG...

Analyst ratings

89%

of 9 ratings
Buy
88.9%
Hold
11.1%
Sell
0%

People also own

Based on the portfolios of people who own URGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.